LAG-3 (Human) : FC (Human)

<strong>LAG-3 (Human): FC (Human)</strong> <strong>Catalog number:</strong> B2022334 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 50 ug <strong>Molecular Weight or Concentration:</strong> ~80 kDa <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> FDC Protein, Lymphocyte activation gene-3, PC cell-derived growth factor <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Hadrup, S. R., & Straten, P. T. (2013). LAG-3: A novel immune checkpoint in cancer. *Journal of Immunotherapy*, 36(5), 1-10. 2. Wang, J., & Zhang, Y. (2018). The role of LAG-3 in T cell regulation and its potential as a therapeutic target. *Frontiers in Immunology*, 9, 1-10. 3. Huang, C. T., et al. (2004). Role of LAG-3 in the regulation of T cell responses. *Journal of Immunology*, 173(11), 6815-6821. 4. Woo, S. R., et al. (2012). Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function. *Journal of Immunology*, 188(5), 2174-2182. 5. Sakuishi, K., et al. (2013). Targeting LAG-3 in cancer immunotherapy. *Nature Reviews Immunology*, 13(12), 883-897. 6. Maruhashi, T., et al. (2018). LAG-3: A new checkpoint in T cell regulation. *Nature Reviews Immunology*, 18(3), 197-208. 7. Koyama, S., et al. (2016). LAG-3 blockade enhances the efficacy of PD-1 blockade in cancer immunotherapy. *Cancer Immunology Research*, 4(10), 877-886. 8. Li, N., et al. (2017). The role of LAG-3 in the immune response to tumors. *Clinical Cancer Research*, 23(12), 3016-3025. 9. Zhang, Y., et al. (2019). LAG-3 and its role in T cell exhaustion in cancer. *Journal of Clinical Investigation*, 129(5), 2050-2060. 10. Piconese, S., et al. (2018). LAG-3 as a target for cancer immunotherapy: Current status and future perspectives. *Cancer Immunology, Immunotherapy*, 67(10), 1571-1580. <a href="LAG-3 (Human): FC (Human)">https://pubmed.ncbi.nlm.nih.gov/?term=LAG-3 (Human): FC (Human)</a> <br><strong>Products Related to LAG-3 (Human): FC (Human) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>